Morishita Shigeru, Arita Seizaburo
Department of Psychiatry, Kawasaki Medical School, 577 Matsushima, Kurashiki, Okayama, Japan.
Hum Psychopharmacol. 2003 Aug;18(6):479-82. doi: 10.1002/hup.508.
Selective serotonin reuptake inhibitors (SSRIs) and dual serotonin and noradrenaline reuptake inhibitors (SNRIs) are the most commonly prescribed class of antidepressants, yet it is not known whether one is superior to another.
The purpose of this clinical practice was to compare the periods of onset of action of fluvoxamine, paroxetine and milnacipran.
A retrospective cohort analysis was carried out among out-patients with depression treated in the Department of Psychiatry, Kawasaki Medical School Hospital, Kurashiki, Japan, in 2000 and 2001. A total of 206 patients receiving fluvoxamine, paroxetine and milnacipran were identified.
The cumulative percentage of responders receiving milnacipran reached over 80% after 4 weeks, but it did reach this level for fluvoxamine or paroxetine until after 6 weeks.
The differential period of onset of action should help guide clinicians in determining a suitable duration of antidepressants for depression.
选择性5-羟色胺再摄取抑制剂（SSRIs）以及5-羟色胺与去甲肾上腺素再摄取双重抑制剂（SNRIs）是最常被处方的一类抗抑郁药，但尚不清楚其中一种是否优于另一种。
本临床实践的目的是比较氟伏沙明、帕罗西汀和米那普明的起效时间。
对2000年和2001年在日本仓敷市川崎医科大学医院精神科接受治疗的抑郁症门诊患者进行回顾性队列分析。共确定了206名接受氟伏沙明、帕罗西汀和米那普明治疗的患者。
接受米那普明治疗的患者在4周后应答者累积百分比达到80%以上，但氟伏沙明或帕罗西汀直到6周后才达到这一水平。
起效时间的差异应有助于指导临床医生确定治疗抑郁症的抗抑郁药的合适疗程。
